Franklin Biotechnology Discovery Fund A(acc)USD

Equity fund

1 year

Globe

USA

Largest region

High

Risk

Annual costs

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Description

  • Fondet investerer hovedsakelig i aksjeverdipapirer utstedt av bioteknologiselskaper av enhver størrelse , og som befinner seg i USA og i andre land Fondet kan investere i mindre omfang i gjeldsobligasjoner av høyere kvalitet utstedt av selskaper Et bioteknologiselskap er et selskap som har minst 50 % av sitt overskudd fra eller er involvert i virksomheter som forskning, utvikling, produksjon og distribusjon av ulike bioteknologiske eller biomedisinske produkter, tjenester og prosesser. Fondet vil normalt investere mer i USA enn i noe annet land.

Investment horizon

  • Franklin Biotechnology Discovery Fund A(acc)USD is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • Price/NAV

    09 Sept 2025

  • Start date
    02 Apr 2000
  • ISIN
    LU0109394709

Risk

  • High (5 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Annual cost

  • Ongoing costs

    Includes management fees of 1,50 %

  • Platform fee
  • Kickback fee
  • Annual running costs

Other costs

  • Performance-based fee
  • Transaction costs
  • Costs for any currency exchanges are not included.

Allocation

  • Stocks 95%
    Interest 5%

Portfolio

Shows the fund's largest investments.

  • Gilead Sciences Inc
    7.1%
  • Amgen Inc
    5.4%
  • Vertex Pharmaceuticals Inc
    5.3%
  • Alnylam Pharmaceuticals Inc
    4.5%
  • argenx SE ADR
    4.5%
  • Regeneron Pharmaceuticals Inc
    4.4%
  • Insmed Inc
    4.1%
  • Jazz Pharmaceuticals PLC
    4.0%
  • Ascendis Pharma AS ADR
    3.5%
  • Merus NV
    2.9%